T-cell therapy in combination with vemurafenib for BRAF mutated metastatic melanoma

Center for Cancer Immune Therapy0 个研究点目标入组 12 人开始时间: 2014年4月11日最近更新: 2019年2月28日

试验速览

暂无简介。

•- Histologically confirmed metastatic or locally advanced malignant melanoma
•- Histopathologically confirmed BRAF mutation
•- Patients must have a resectable lesion
•- Patients must be between 18 years and 70 years of age and must have measurable disease
•- Patients must have a clinical performance status of ECOG 0 or 1.
•- Adequate organ function
•- Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for six months after receiving the preparative regimen.
•- Patients must be able to understand and sign the Informed Consent document.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•- Patients with other cancers within 5 years
•- Patients with ocular melanoma
•- Former treatment with BRAF inhibitor
•- Serious comorbity or autoimmune disease
•- Requirement for immunosuppressive doses of systemic corticosteroids or other immunosuppressive drugs
•- Patients who have any CNS lesion that is symptomatic or show significant surrounding edema on MRI scan will not be eligible until they have been treated and demonstrated no clinical or radiologic CNS progression for at least 1 month.
•- Other anticancer treatment within 28 days

发起方

Center for Cancer Immune Therapy